Lv32
320 积分 2024-01-28 加入
Camrelizumab plus chemotherapy as induction therapy followed by concurrent chemoradiotherapy and camrelizumab consolidation in limited-stage small cell lung cancer: a randomized phase II trial
9小时前
已完结
Pulmonary nodules: classification, biomarkers, signaling pathways, diseases, early diagnosis and management
9小时前
已完结
The Five-Decade Journey of Small Cell Lung Cancer
1天前
已完结
IARC Perspective on Lung Cancer Screening
17天前
已完结
Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial
1个月前
已完结
Ifebemtinib plus garsorasib in previously treated metastatic colorectal cancer with KRASG12C mutation: a multicentre, randomised, phase 1b/2 trial
1个月前
已完结
Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial
1个月前
已完结
Transarterial Chemoembolization Plus Thermal Ablation in Unresectable Hepatocellular Carcinoma: The Phase 3 TORCH Randomized Clinical Trial
1个月前
已完结
Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer
2个月前
已完结
Ensartinib in Resected ALK-Positive Non-Small-Cell Lung Cancer
3个月前
已完结
皖公网安备34019202002308
